Abstract

A double-blind placebo-controlled randomised clinical trial was conducted on 41 patients with non-alcoholic fatty liver disease (NAFLD). Participants were randomly allocated to receive either a cranberry supplement or a placebo for 12 weeks. Both groups were assigned to follow a weight loss diet. At the end of the study, alanine aminotransferase and insulin decreased significantly in both groups (p < .05); however, this reduction was significantly greater in the cranberry group than in the placebo group (p < .05). Significant improvements in insulin resistance were observed in the cranberry group and between the two groups (p < .001 and p = .020, respectively). Also, there was an improvement in steatosis grade and anthropometric measurements in both groups (p < .05), and there was no significant difference between the two groups in regard to these factors (p > .05). It seems that 288 mg of cranberry extract might improve managing NAFLD, which is equivalent to 26 g of dried cranberry.

摘要

对41例非酒精性脂肪肝疾病（NAFLD）的患者进行了双盲安慰剂对照的随机临床试验。参与者被随机分配接受蔓越莓补充剂或安慰剂治疗12周。两组均接受减肥饮食。在研究结束时，两组丙氨酸转氨酶和胰岛素均显着降低（p  <.05）；然而，酸果蔓组的这种减少明显大于安慰剂组（p  <.05）。蔓越莓组和两组之间的胰岛素抵抗显着改善（p  <.001和p 分别为.020）。此外，两组的脂肪变性等级和人体测量指标均有改善（p  <.05），而在这些因素方面，两组之间也没有显着差异（p  > .05）。288克蔓越莓提取物似乎可以改善NAFLD的管理，相当于26克干蔓越莓。